share_log

Breaking Down Biogen: 18 Analysts Share Their Views

Benzinga ·  Jan 28 14:00

Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:BIIB), expressing a variety of opinions spanning from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings431100
Last 30D00100
1M Ago10200
2M Ago00300
3M Ago33500

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of $300.00, and a low estimate of $138.00. A 16.73% drop is evident in the current average compared to the previous average price target of $257.94.

bigjpg

Interpreting Analyst Ratings: A Closer Look

The standing of Biogen among financial...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 412

Recommended

Write a comment